About preCARDIA
preCARDIA is a Healthcare company based in Saint Paul (United States) founded in 2016, and was acquired by Abiomed in June 2021. A device for treating acute decompensated heart failure is developed. It operates on a HealthTech model. Its chief executive, as recorded, is Lisa Wipperman Heine. The company was acqui-hired. preCARDIA offers products and services including preCARDIA System. Its focus areas include Medical Devices and Cardiovascular Devices. Its competitors include CVRx, HeartWare and Element Science; 3 of its 3 listed competitors have raised funding.
Company details
preCARDIA is engaged in developing innovative medical devices aimed at treating acute decompensated heart failure (ADHF). The companys proprietary catheter and controller system is designed to reduce cardiac filling pressures and promote decongestion, improving cardiac and renal function. Solutions are targeted at heart failure specialists to provide minimally invasive interventions. The technology addresses a critical need in healthcare by offering potential reductions in hospital stays and re-hospitalizations for ADHF patients. Operations are centered in the healthcare sector with a focus on cardiovascular care.
- Headquarters Saint Paul, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website precardia.com
- Social LinkedIn
- Acquired by Abiomed (Jun 2021)
Products & Services of preCARDIA
preCARDIA offers a comprehensive portfolio of products and services, including preCARDIA System.
Designed to treat acute decompensated heart failure effectively.
Investors in preCARDIA
preCARDIA has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Abiomed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Heart pumps are developed for blood circulation and oxygenation support. | 1981 | abiomed.com | Danvers, United States |
Investor details for preCARDIA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of preCARDIA
1 people are tracked at preCARDIA (1 in leadership).
| Name | Role | Group |
|---|---|---|
Lisa Wipperman Heine | CEO | Leadership |
Complete people profiles for preCARDIA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of preCARDIA
2 dated milestones of preCARDIA across 5 years, from founding to its latest funding, stage changes and deals.
- Founded preCARDIA is founded.
- Exit Acquired by Abiomed.
Competitors of preCARDIA
preCARDIA has 3 listed competitors in our database, 3 of them funded. They include CVRx, HeartWare and Element Science.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cvrx.com | 2001 | Minneapolis, United States | $368.5M | 142 | Implantable technology for hypertension and heart failure is developed. | |
| heartware.com | 2005 | Framingham, United States | $12.38M | 547 | Miniaturized ventricular assist devices are developed for heart failure treatment. | |
| elementscience.com | 2013 | San Francisco, United States | $192.6M | Wearable patch defibrillators are developed for sudden cardiac arrest treatment. |
Detailed competitors of preCARDIA
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as preCARDIA (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about preCARDIA
preCARDIA was founded in 2016.
preCARDIA is headquartered in Saint Paul, United States. It is registered at Saint Paul, Minnesota, United States.
Lisa Wipperman Heine is the CEO of preCARDIA, as recorded in our data.
preCARDIA is engaged in developing innovative medical devices aimed at treating acute decompensated heart failure (ADHF). The companys proprietary catheter and controller system is designed to reduce cardiac filling pressures and promote decongestion, improving cardiac and renal function. Solutions are targeted at heart failure specialists to provide minimally invasive interventions. The technology addresses a critical need in healthcare by offering potential reductions in hospital stays and re-hospitalizations for ADHF patients. Operations are centered in the healthcare sector with a focus on cardiovascular care.
preCARDIA's top competitors include CVRx, Element Science and HeartWare.
preCARDIA offers preCARDIA System.
preCARDIA has 1 investor. Key investors include Abiomed.
Yes. preCARDIA was acquired by Abiomed in June 2021.